ARTICLE | Strategy
Change of phase
May 5, 2008 7:00 AM UTC
Since its inception in 2002, Phase Bioscience Inc. has been purifying recombinant proteins and antibodies as a service for others using technologies based on elastin-like polypeptides. Having raised $7.7 million last October and with a new CEO on board, the company now aims to use those technologies to develop therapeutics for its own account, initially for diabetes and cancer.
"At Phase Bioscience, I saw a diamond in the rough, and I'm redirecting and refocusing the company to develop next-generation biopharmaceuticals, which was not the original focus of the company," said CEO Chris Prior, who joined last week...